Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

BELITE BIO, INC Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results · Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease with 100 subjects enrolled across 11 countries worldwide · First subject dosed with Tinlarebant in pivotal global Phase 3 “PHOENIX” trial in Geographic Atrophy · Oral, once-daily Tinlarebant continues to be safe and well tolerated, slowing expansion of autofluorescence, reducing incident atrophic retinal lesion growth rate, and stabilizing visual acuity up to 18-months in Phase 2 STGD1 trial · Strengthened balance sheet with $30 million of gross proceeds from the underwritten public offering · Final 2-year data of LBS-008-CT02 in STGD1 expected in Q4 2023 and interim Ph..."
07/24/2023 6-K Quarterly results
06/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Sales Agreement, by and between Belite Bio, Inc and SVB Securities LLC and Cantor Fitzgerald & Co",
"Opinion of Maples and Calder (Hong Kong) LLP"
06/16/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/01/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/31/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results"
05/10/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/01/2023 F-3 Form F-3 - Registration statement by foreign private issuers:
04/25/2023 6-K Quarterly results
03/31/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
02/14/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
12/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Securities and Exchange Commission 100 F Street, N.E."
11/18/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant · Tinlarebant is Belite Bio’ s orally administered tablet intended as an early intervention to slow disease progression in patients affected with Stargardt Disease and Dry Age-related Macular Degeneration · There are currently no approved treatments for STGD1 and Dry AMD · Currently, a 2-year Phase 2 study in adolescent STGD1 patients is ongoing and a global Phase 3 study in adolescent STGD1 patients is recruiting subjects · 12-month interim data from the ongoing Phase 2 STGD1study continues to show halting or slowing of lesion growth · Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease Designation in the U.S., and Orphan Drug Desi..."
10/03/2022 6-K Quarterly results
09/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China · LBS-008 is Belite Bio’ s orally administered tablet for early intervention to maintain the health of retinal tissue in Stargardt disease and Dry AMD patients · A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing · The Phase 3 trial named “DRAGON” is a Multi-center, Randomized, Double Masked, Placebo Controlled Study to Evaluate the Safety and Efficacy of TinlaRebant in the Treatment of StArGardt Disease in AdOlesceNt Subjects has commenced in the U.S., the United Kingdom, Germany, Belgium, Switzerland, Hong Kong, Taiwan, and Australia, with several patients already enrolled · LBS-008, Belite Bio’ s lead asset, has been granted Fast Track De..."
08/22/2022 6-K Quarterly results
08/10/2022 6-K Quarterly results
07/19/2022 6-K Quarterly results
07/08/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/12/2022 6-K Quarterly results
05/03/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Belite Bio Receives FDA Fast Track Designation For LBS-008"
04/29/2022 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
04/29/2022 EFFECT Form EFFECT - Notice of Effectiveness:
04/29/2022 EFFECT Form EFFECT - Notice of Effectiveness:
04/27/2022 F-1/A Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
04/25/2022 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
04/25/2022 CERT Form CERT - Certification by an exchange approving securities for listing:
04/22/2022 F-1/A Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
04/20/2022 F-6 Form F-6 - Registration of American Depository Receipt shares, not immediately effective:
04/20/2022 8-A12B Form 8-A12B - Registration of securities [Section 12(b)]:
04/20/2022 FWP Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses:
04/20/2022 F-1/A Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
04/05/2022 F-1 Form F-1 - Registration statement for certain foreign private issuers:

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy